Recently, the "New Complex Antibody Medicine Development" sub-forum of the 11th Beijing E-Town (Beijing-Tianjin-Hebei) Biomedical Industry Conference was held in Beijing E-Town. 

According to the meeting, the world's first specific medicine for membranous nephropathy, a deterioration of kidney function, may emerge from Beijing E-Town.

"The phase II clinical study of the new antibody MIL62 for the treatment of membranous nephropathy showed complete kidney remission rates of 33.3 percent and 46.9 percent at 52 weeks and 76 weeks of long-term follow-up, respectively, both significantly better than the control medicine group," said Li Feng, chairman and general manager of Beijing Mabworks Biotech Co, during the forum. 

Li provided a detailed introduction to the company's independently developed CD20 antibody MIL62.

Tian Guangshi has been engaged in the research and development of innovative large-molecule antibody medicines for many years, with several drugs advancing to phase III clinical trials. 

MIL62 is expected to apply for listing next year and is likely to become the world's first approved specific drug for membranous nephropathy.

"In the past years, we have received a lot of support from Beijing E-Town, which has laid a solid foundation for the development of our company," Li Feng stated in an interview.

Wang Minghan, founder and CEO of Van Enshi Pharmaceutical (Beijing) Co, highlighted the company's three innovative platforms — PACbody, SPECpair, and ATACCbody — as well as the rapid progress of two bispecific antibodies, PT886 and PT217, both of which have received FDA Fast Track designation.

Additionally, representatives from four other companies and research institutes delivered speeches on overcoming ADC resistance through transforming "cold tumors" into "hot tumors," the development of new immune bispecific antibody medicines for targeted therapeutics, and the research progress of bispecific antibody and bispecific antibody ADC in lung cancer.